Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects

Abstract

Background: A high prevalence of tobacco smoking has been observed in methamphetamine users, but there have been no in vivo brain neurochemistry studies addressing gender effects of tobacco smoking in methamphetamine users. Methamphetamine addiction is associated with increased risk of depression and anxiety in females. There is increasing evidence that selective analogues of nicotine, a principal active component of tobacco smoking, may ease depression and improve cognitive performance in animals and humans. Objectives: To investigate the effects of tobacco smoking and gender on brain phosphocreatine (PCr) levels, a marker of brain energy metabolism reported to be reduced in methamphetamine-dependent subjects. Methods: Thirty female and 27 male methamphetamine-dependent subjects were evaluated with phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS) to measure PCr levels within the pregenual anterior cingulate, which has been implicated in methamphetamine neurotoxicity. Results: Analysis of covariance revealed that there were statistically significant slope (PCr versus lifetime amount of tobacco smoking) differences between female and male methamphetamine-dependent subjects (p = 0.03). In females, there was also a statistically significant interaction between lifetime amounts of tobacco smoking and methamphetamine in regard to PCr levels (p = 0.01), which suggests that tobacco smoking may have a more significant positive impact on brain PCr levels in heavy, as opposed to light to moderate, methamphetamine-dependent females. Conclusion: These results indicate that tobacco smoking has gender-specific effects in terms of increased anterior cingulate high energy PCr levels in methamphetamine-dependent subjects. Cigarette smoking in methamphetamine-dependent women, particularly those with heavy methamphetamine use, may have a potentially protective effect upon neuronal metabolism.

• Methamphetamine
• MRS
• neuroimaging
• phosphocreatine
• Tobacco smoking
• women

Funding

This study was supported by funding from NIH 1R01DA027135 and Utah Science Technology and Research initiative (USTAR) funds to Dr. Renshaw and Dr. Yurgelun-Todd.

Declaration of interest

Dr. Renshaw is a consultant for Kyowa Hakko and Ridge Diagnostics. Dr. Yurgelun-Todd has research support from Kyowa Hakko, Takeda, and Otsuka. The authors alone are responsible for the content and writing of this paper.